Baxalta Incorporated (NYSE: BXLT) reported positive results from a Phase 1 open-label, dose escalation study assessing the safety and pharmacokinetic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE